Overview

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Status:
Recruiting

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Phase:

Phase 4

Details

Lead Sponsor:

Currax Pharmaceuticals

Treatments:

Bupropion
Naltrexone